BIO-TECHNE Corp·4

Nov 3, 5:25 PM ET

Seth Alpna 4

4 · BIO-TECHNE Corp · Filed Nov 3, 2025

Insider Transaction Report

Form 4
Period: 2025-10-30
Seth Alpna
Director
Transactions
  • Award

    Common Stock

    2025-10-30+1,64015,411 total
  • Award

    Stock Options (Right to Buy)

    2025-10-30+3,7773,777 total
    Exercise: $60.96Exp: 2035-10-30Common Stock (3,777 underlying)
Holdings
  • Stock Options (Right to Buy)

    Exercise: $63.92From: 2021-10-28Exp: 2030-10-29Common Stock (6,028 underlying)
    6,028
  • Stock Options (Right to Buy)

    Exercise: $128.81From: 2022-10-27Exp: 2031-10-28Common Stock (2,532 underlying)
    2,532
  • Stock Options (Right to Buy)

    Exercise: $50.41From: 2020-10-24Exp: 2029-10-24Common Stock (8,044 underlying)
    8,044
  • Stock Options (Right to Buy)

    Exercise: $61.51From: 2024-10-24Exp: 2033-10-26Common Stock (3,937 underlying)
    3,937
  • Stock Options (Right to Buy)

    Exercise: $73.94From: 2023-10-26Exp: 2032-10-27Common Stock (3,460 underlying)
    3,460
  • Stock Options (Right to Buy)

    Exercise: $68.37From: 2025-10-24Exp: 2034-10-24Common Stock (3,511 underlying)
    3,511
Footnotes (1)
  • [F1]The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES